$IMNM

Immunome Inc. (IMNM): Submission of Matters to a Vote of Security Holders

Immunome Inc. (IMNM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001472012 0001472012 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2

Original reporting
Published Jun 12, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$IMNM
Neutral
high confidence
Mentioned
$IMNM
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IMNMNeutralLow
01

Why it matters

Confirms election of three Class III directors and ratification of Ernst & Young LLP; advisory votes approved executive compensation and set preferred advisory vote frequency to annually.

02

Market read

Primarily governance/administrative disclosure; useful for confirming board and proxy outcomes but not a standalone catalyst.

03

What to watch

Advisory say-on-frequency results (1 year) may matter for future proxy negotiations, but it is not a binding change and typically has limited near-term trading impact.

Relevance 6/10Novelty 3/10Timing: Filed after the June 9, 2026 annual meeting (June 12, 2026 filing).

Background

The SEC 8-K (Item 5.07) summarizes final shareholder vote results from Immunome’s June 9, 2026 annual meeting.

Company-level read

Ticker impact

$IMNMNeutralHigh confidence
Context

Immunome filed an 8-K reporting final results of its June 9, 2026 annual meeting votes, including director elections and executive comp items.

Expected impact

Low likelihood of a sustained price move solely from these vote tallies; any reaction would be short-lived unless tied to other contemporaneous events.

Evidence & confidence

The filing discloses final voting results (directors, auditor ratification, advisory say-on-pay and say-on-frequency) without new financial guidance, transactions, or regulatory actions.

Market effects

Minimal; this is company-specific governance disclosure with no sector-wide regulatory or clinical signal.

None indicated.

None indicated.

Counterpoint

If traders were positioned around governance/board-change expectations, the vote totals could reduce uncertainty, but the article still lacks any new strategic or financial catalyst.

Key entities

  • Immunome, Inc.

    Company filing the 8-K and reporting final annual meeting vote results.

  • Ernst & Young LLP

    Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.

  • Class III directors (James Boylan, Sandra Swain, Philip Wagenheim)

    Elected to serve until the 2029 annual meeting per the reported vote totals.

Related articles

$IMNMMed

What This Immunome Sale Means a Day Before a Big FDA Milestone

Immunome reported $582.7M cash as of March 31 and a Q1 net loss of $53.8M. The article says an insider sale occurred via a preset plan as the FDA accepted Immunome’s varegacestat NDA for review. It cites an FDA decision date of April 28, 2027, based on Phase 3 data showing an 84% lower risk of progression.

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

$MTZMed

Is MasTec’s Debt Raise and Upgraded Guidance Altering The Investment Case For MasTec (MTZ)?

MasTec (MTZ) completed a $647.76 million fixed-rate senior unsecured notes offering with a 5.85% coupon due Sept. 30, 2036. The company reported Q2 2026 sales of $4,373.55 million and net income of $130.12 million, and raised full-year 2026 revenue guidance to $18.2 billion and GAAP net income to $539 million, citing balance-sheet flexibility and governance updates.